Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated radiation dose with concurrent sorafenib for unresectable
hepatocellular carcinoma that has not responded to transarterial chemoembolization.